NCT06928753

Real-world Effectiveness, Safety and Immunogenicity of Chikungunya Vaccination in Populations at Risk of Severe or Complicated Forms: Prospective Study in La Réunion

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 1,800 (estimated)
• Sponsor: Centre Hospitalier Universitaire de la Réunion · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Against the backdrop of a growing chikungunya epidemic in La Réunion, this prospective study will assess the real-life efficacy, safety and immunogenicity of IXCHIQ® vaccine in vulnerable individuals (seniors, comorbid patients), defined by the French Health Autority (HAS) as at risk of severe or complicated forms and/or chronic disabling forms (chronic arthritis, chronic fatigue phenotypes). This study will also provide input for the preparation of a cluster randomized trial on a population scale.

Conditions

• Chikungunya Virus Infection

Interventions

Type	Name	Description
BIOLOGICAL	IXCHIQ	Group of vaccinated arm will be with the IXCHIQ vaccine

Timeline

• Start date: 2025-04-18
• Primary completion: 2026-04-01
• Completion: 2026-10-01
• First posted: 2025-04-15
• Last updated: 2025-07-29

Locations

1 site across 1 country: France